Efficacy and Safety of Rivaroxaban for Extremely Aged Patients with Venous Thromboembolism: A Retrospective, Cross-Sectional Real-World Study

Figures & data

Table 1 Baseline Characteristics

General Characteristics, M (SD)	Rivaroxaban (n=121)
Age (years)	85.0 + 3.9
Woman, % (n)	52.89 (64)
Weight (kg)	61.3 + 10.5
Body mass index (kg/m^2)	22.9 + 3.6
Charlson comorbidity index (score)	7.1 + 2.8
Serum creatinine	81.4 + 51.1
eGFR (mL/min)	56.7 + 23.6
Haemoglobin (g/dL)	118 + 21.6
Daily dose (without loading dose), % (n)	88.43 (107)
5mg, % (n)	1.65 (2)
7.5mg, % (n)	0.83 (1)
10mg, % (n)	50.41 (61)
15mg, % (n)	20.66 (25)
20mg, % (n)	14.88 (18)
Daily dose (with loading dose), % (n)	11.57 (14)
15/10mg, % (n)	1.65 (2)
20/10mg, % (n)	7.43 (9)
30/20mg, % (n)	1.65 (2)
30/20/10mg, % (n)	0.83 (1)

Notes: M (SD), mean (standard deviation); % (n), percentage (count).

Abbreviation: eGFR, glomerular filtration rate estimated using the Cockcroft–Gault formula.

Figure 1 Flow chart.

Table 2 Efficacy and Safety of Rivaroxaban Classified by Multiplex Dosage Regimen

Daily Dose	Hemorrhages, % (n)	Thrombus Disappeared, % (n)
Without loading dose (mg)	10.28 (11)	93.45 (100)
5	0 (0)	66.67 (2)
7.5	0 (0)	100 (1)
10	9.68 (6)	91.94 (57)
15	12.50 (3)	95.83 (23)
20	11.76 (2)	100 (17)
With loading dose (mg)	7.14 (1)	100 (14)
15/10	0 (0)	100 (2)
20/10	0 (0)	100 (9)
30/20/10	0 (0)	100 (1)
30/20	50 (1)	100 (2)

Note: % (n), percentage (count).

Figure 2 Pattern of rivaroxaban dose associated safety observation. (A) Cases of hemorrhages in different dose gradients without loading. (B) Percentage of hemorrhages in different dose gradients without loading. (C) Cases of hemorrhages in different dose gradients with loading. (D) Percentage of hemorrhages in different dose gradients without loading. (E) Cases of hemorrhages in different loading conditions. (F) Percentage of hemorrhages in different loading conditions.

Figure 3 Pattern of rivaroxaban dose associated efficacy observation. (A) Cases of thrombus persisting in different dose gradients without loading. (B) Percentage of thrombus persisting in different dose gradients without loading. (C) Cases of thrombus persisting in different dose gradients with loading. (D) Percentage of thrombus persisting in different dose gradients with loading. (E) Cases of thrombus persisting in different loading conditions. (F) Percentage of thrombus persisting in different loading conditions.

Figure 4 Pattern of complication or comorbidity associated safety observation. (A) Cases of hemorrhages in patients with and without malignancy. (B) Cases of hemorrhages in 10mg rivaroxaban recipients with and without malignancy. (C) Cases of hemorrhages in patients with and without infection. (D) Cases of hemorrhages in 10mg rivaroxaban recipients with and without infection. (E) Cases of hemorrhages in patients with different eGFR levels. (F) Cases of hemorrhages in 10mg rivaroxaban recipients with different eGFR levels. Note: eGFR = glomerular filtration rate estimated using the Cockcroft–Gault formula.

Figure 5 Pattern of complication or comorbidity associated efficacy observation. (A) Cases of thrombus persisting in patients with and without malignancy. (B) Cases of thrombus persisting in 10mg rivaroxaban recipients with and without malignancy. (C) Cases of thrombus persisting in patients with and without infection. (D) Cases of thrombus persisting in 10mg rivaroxaban recipients with and without infection. (E) Cases of thrombus persisting in patients with different eGFR levels. (F) Cases of thrombus persisting in 10mg rivaroxaban recipients with different eGFR levels. Note: eGFR = glomerular filtration rate estimated using the Cockcroft–Gault formula.

Figure 6 Efficacy and safety outcomes of patients with different ACCI scores. (A) Cases of hemorrhages in patients with different ACCI scores. (B) Cases of hemorrhages in 10mg rivaroxaban recipients with different ACCI scores. (C) Cases of thrombus persisting in patients with different ACCI scores. (D) Cases of hemorrhages in 10mg rivaroxaban recipients with different ACCI scores. Note: ACCI= age-adjusted Charlson comorbidity index. *P<0.05.

Data Sharing Statement

The raw data required to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study. Data are, however, available from the authors upon reasonable request and with permission of the corresponding author (Wangshu Dai).